Lotus Pharmaceutical Co Ltd Market Cap ($1.40 Billion)
Market Cap & Net Worth: Lotus Pharmaceutical Co Ltd (1795)
Lotus Pharmaceutical Co Ltd market cap. Lotus Pharmaceutical Co Ltd (TW:1795) has a market capitalization of $1.40 Billion (NT$44.57 Billion) as of November 1, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #7200 globally and #228 in its home market, demonstrating a -4.83% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lotus Pharmaceutical Co Ltd's stock price NT$167.50 by its total outstanding shares 266090757 (266.09 Million). Also see Lotus Pharmaceutical Co Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Lotus Pharmaceutical Co Ltd Market Cap History (2015–2026)
Lotus Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows growth from $572.33 Million to $1.40 Billion (8.00% CAGR). Check Lotus Pharmaceutical Co Ltd (1795) share price today for real-time trading data and today's change.
Lotus Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lotus Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Lotus Pharmaceutical Co Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.12x
Lotus Pharmaceutical Co Ltd's market cap is 0.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.50x
Lotus Pharmaceutical Co Ltd's market cap is 0.50 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $493.28 Million | $5.90 Billion | -$134.04 Million | 0.08x | N/A |
| 2017 | $419.99 Million | $6.42 Billion | $7.68 Million | 0.07x | 54.65x |
| 2018 | $610.22 Million | $6.43 Billion | $99.48 Million | 0.09x | 6.13x |
| 2019 | $947.03 Million | $9.17 Billion | $662.81 Million | 0.10x | 1.43x |
| 2020 | $658.80 Million | $10.73 Billion | $1.03 Billion | 0.06x | 0.64x |
| 2021 | $805.55 Million | $12.65 Billion | $1.40 Billion | 0.06x | 0.57x |
| 2022 | $2.06 Billion | $14.63 Billion | $3.02 Billion | 0.14x | 0.68x |
| 2023 | $2.28 Billion | $16.96 Billion | $4.11 Billion | 0.13x | 0.56x |
| 2024 | $2.26 Billion | $18.58 Billion | $5.07 Billion | 0.12x | 0.45x |
| 2025 | $2.37 Billion | $20.51 Billion | $4.72 Billion | 0.12x | 0.50x |
Competitor Companies of 1795 by Market Capitalization
Companies near Lotus Pharmaceutical Co Ltd in the global market cap rankings as of November 1, 2026. Also see Lotus Pharmaceutical Co Ltd total assets for a full breakdown of the balance sheet.
Key companies related to Lotus Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Lotus Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Lotus Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Lotus Pharmaceutical Co Ltd's market cap moved from $572.33 Million to $ 1.40 Billion, with a yearly change of 8.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$1.40 Billion | -40.81% |
| 2025 | NT$2.37 Billion | +5.01% |
| 2024 | NT$2.26 Billion | -0.92% |
| 2023 | NT$2.28 Billion | +10.57% |
| 2022 | NT$2.06 Billion | +156.01% |
| 2021 | NT$805.55 Million | +22.28% |
| 2020 | NT$658.80 Million | -30.43% |
| 2019 | NT$947.03 Million | +55.20% |
| 2018 | NT$610.22 Million | +45.29% |
| 2017 | NT$419.99 Million | -14.86% |
| 2016 | NT$493.28 Million | -13.81% |
| 2015 | NT$572.33 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Lotus Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.40 Billion USD |
| MoneyControl | $1.40 Billion USD |
| MarketWatch | $1.40 Billion USD |
| marketcap.company | $1.40 Billion USD |
| Reuters | $1.40 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lotus Pharmaceutical Co Ltd
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines;… Read more